Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
复制标题
DOI：
10.1016/j.jtho.2016.04.028
复制
发表时间：
2016-08
期刊：
影响因子：
--
通讯作者：
Malik S
中科院分区：
文献类型：
--
作者：
Carbone M;Kanodia S;Chao A;Miller A;Wali A;Weissman D;Adjei A;Baumann F;Boffetta P;Buck B;de Perrot M;Dogan AU;Gavett S;Gualtieri A;Hassan R;Hesdorffer M;Hirsch FR;Larson D;Mao W;Masten S;Pass HI;Peto J;Pira E;Steele I;Tsao A;Woodard GA;Yang H;Malik S
2015年11月9日和10日，暴露于天然蜂窝状纤维的人群间皮瘤国际会议在夏威夷火奴鲁鲁的夏威夷大学癌症中心举行。这次会议是由国际肺癌研究协会共同主办的，议程的设计得到了美国国家癌症研究所和国家环境健康科学研究所工作人员的大力支持。一个多学科的与会者小组介绍了反映一系列学科观点的最新情况，包括矿物学、地质学、流行病学、毒理学、生物化学、分子生物学、遗传学、公共卫生和临床肿瘤学。该小组确定了知识差距是预防和治疗恶性间皮瘤(MM)的障碍，以及解决障碍所需的下一步步骤。这篇手稿报告了该组织的努力，并将重点放在限制人口风险和减少MM发病率的战略上。探讨了四个主要主题：遗传风险、环境暴露、生物标记物和临床干预。当疾病发生在生殖系BRCA1相关蛋白1突变的携带者时，遗传学在多发性骨髓瘤中起着关键作用。此外，似乎除了BRCA1相关蛋白1之外，其他未知的遗传变异也可能影响多发性骨髓瘤的个体风险，特别是在暴露于石棉和相关矿物质纤维之后。MM是一种几乎完全可以预防的恶性肿瘤，因为它最常见的原因是接触了商业石棉或具有类似石棉的健康影响的矿物纤维，如埃利奥特。在过去，在北美和欧洲，最突出的接触来源与职业有关。目前的法规减少了这些国家的职业接触；然而，一些人继续在较旧的建筑和其他环境中接触以前安装的石棉。此外，越来越多的人在农村地区接触到土壤或岩石中含有非商业性石棉、埃里昂和其他矿物纤维(称为天然石棉[NOA])并正在开发中的石棉。公共卫生当局、科学家、居民和其他受影响群体必须在环境中记录有石棉暴露(包括NOA)的地区共同努力，以减轻或减少这种暴露。尽管目前还没有有效的血液生物标记物在石棉/NOA暴露人群的早期阶段用于筛查和识别多发性骨髓瘤，但在会议上提出的新的生物标记物，如高迁移率组盒1和纤毛蛋白-3，是有希望的。人们普遍认为，目前对多发性骨髓瘤的治疗是基于手术和标准化疗，对总体存活率(OS)影响不大，仍然令人沮丧。此外，尽管临床试验中正在开发和探索急需的多发性骨髓瘤新的治疗方法，但迫切需要投资于预防研究，这是降低多发性骨髓瘤发病率和死亡率的大好机会。
On November 9 and 10, 2015, the International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of Hawaii Cancer Center in Honolulu, Hawaii. The meeting was cosponsored by the International Association for the Study of Lung Cancer, and the agenda was designed with significant input from staff at the U.S. National Cancer Institute and National Institute of Environmental Health Sciences. A multidisciplinary group of participants presented updates reflecting a range of disciplinary perspectives, including mineralogy, geology, epidemiology, toxicology, biochemistry, molecular biology, genetics, public health, and clinical oncology. The group identified knowledge gaps that are barriers to preventing and treating malignant mesothelioma (MM) and the required next steps to address barriers. This manuscript reports the group’s efforts and focus on strategies to limit risk to the population and reduce the incidence of MM. Four main topics were explored: genetic risk, environmental exposure, biomarkers, and clinical interventions. Genetics plays a critical role in MM when the disease occurs in carriers of germline BRCA1 associated protein 1 mutations. Moreover, it appears likely that, in addition to BRCA1 associated protein 1, other yet unknown genetic variants may also influence the individual risk for development of MM, especially after exposure to asbestos and related mineral fibers. MM is an almost entirely preventable malignancy as it is most often caused by exposure to commercial asbestos or mineral fibers with asbestos-like health effects, such as erionite. In the past in North America and in Europe, the most prominent source of exposure was related to occupation. Present regulations have reduced occupational exposure in these countries; however, some people continue to be exposed to previously installed asbestos in older construction and other settings. Moreover, an increasing number of people are being exposed in rural areas that contain noncommercial asbestos, erionite, and other mineral fibers in soil or rock (termed naturally occurring asbestos [NOA]) and are being developed. Public health authorities, scientists, residents, and other affected groups must work together in the areas where exposure to asbestos, including NOA, has been documented in the environment to mitigate or reduce this exposure. Although a blood biomarker validated to be effective for use in screening and identifying MM at an early stage in asbestos/ NOA-exposed populations is not currently available, novel biomarkers presented at the meeting, such as high mobility group box 1 and fibulin-3, are promising. There was general agreement that current treatment for MM, which is based on surgery and standard chemotherapy, has a modest effect on the overall survival (OS), which remains dismal. Additionally, although much needed novel therapeutic approaches for MM are being developed and explored in clinical trials, there is a critical need to invest in prevention research, in which there is a great opportunity to reduce the incidence and mortality from MM.
登录
查看更多内容
影响因子：
10.4
作者：
Baumann, Francine;Maurizot, Pierre;Robineau, Bernard
通讯作者：
Robineau, Bernard
影响因子：
11.5
作者：
Carbone, Michele;Yang, Haining
通讯作者：
Yang, Haining
影响因子：
5.3
作者：
Boeluekbas, Servet;Manegold, Christian;Schirren, Joachim
通讯作者：
Schirren, Joachim
影响因子：
9.8
作者：
Ardizzone, Michele;Vizio, Carlotta;Belluso, Elena
通讯作者：
Belluso, Elena
影响因子：
2.9
作者：
Buck, Brenda J.;Goossens, Dirk;Freudenberger, Frederick
通讯作者：
Freudenberger, Frederick